Chrysophanic Acid
CAS No. 481-74-3
Chrysophanic Acid ( Chrysophanic Acid; NSC 37132; NSC 646567; Turkey Rhubarb )
Catalog No. M14613 CAS No. 481-74-3
Extracted from Rheum palmatum L.;Suitability:Boiling ethanol,benzene,chloroform,ether,acetic acid and acetone.
Purity : >98%(HPLC)
Size | Price / USD | Stock | Quantity |
50MG | 29 | In Stock |
|
100MG | 43 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameChrysophanic Acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionExtracted from Rheum palmatum L.;Suitability:Boiling ethanol,benzene,chloroform,ether,acetic acid and acetone.
-
DescriptionExtracted from Rheum palmatum L.;Suitability:Boiling ethanol,benzene,chloroform,ether,acetic acid and acetone;Store the product in sealed,cool and dry condition.
-
SynonymsChrysophanic Acid; NSC 37132; NSC 646567; Turkey Rhubarb
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number481-74-3
-
Formula Weight254.24
-
Molecular FormulaC15H10O4
-
Purity>98%(HPLC)
-
SolubilityDMSO: 5 mg/mL warmed (19.66 mM)
-
SMILESO=C1C2=C(C=CC=C2O)C(C3=CC(C)=CC(O)=C13)=O
-
Chemical Name1,8-dihydroxy-3-methylanthracene-9,10-dione
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
ZD-4190
ZD-4190 is a inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling used for the treatment of cancer.
-
EGFR-IN-7
EGFR-IN-7 is a selective and potent EGFR kinase inhibitor.TQB3804 displayed potent enzymatic activities for EGFRd746-750/T790M/C797S, EGFRL858R/T790M/C797S, EGFRd746-750/T790M, and EGFRL858R/T790M with IC50 of 0.46, 0.13, 0.26, and 0.19 nM respectively, and has similar enzymatic activity for EGFRWT (IC50 = 1.07) to Osimertinib.
-
Mutated EGFR-IN-1
Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.